Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 172.19
LCI's Cash to Debt is ranked higher than
87% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. LCI: 172.19 )
LCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 172.19

Equity to Asset 0.90
LCI's Equity to Asset is ranked higher than
95% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. LCI: 0.90 )
LCI' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.9
Current: 0.9

-0.17
0.9
Interest Coverage 677.61
LCI's Interest Coverage is ranked higher than
72% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. LCI: 677.61 )
LCI' s 10-Year Interest Coverage Range
Min: 1.15   Max: 677.61
Current: 677.61

1.15
677.61
F-Score: 7
Z-Score: 35.43
M-Score: -1.98
WACC vs ROIC
22.00%
78.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 52.74
LCI's Operating margin (%) is ranked higher than
98% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. LCI: 52.74 )
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 52.74

-119.46
46.27
Net-margin (%) 34.24
LCI's Net-margin (%) is ranked higher than
97% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. LCI: 34.24 )
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 34.24

-73
28.64
ROE (%) 41.79
LCI's ROE (%) is ranked higher than
98% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. LCI: 41.79 )
LCI' s 10-Year ROE (%) Range
Min: -38.23   Max: 117.18
Current: 41.79

-38.23
117.18
ROA (%) 36.72
LCI's ROA (%) is ranked higher than
99% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. LCI: 36.72 )
LCI' s 10-Year ROA (%) Range
Min: -28.9   Max: 50.98
Current: 36.72

-28.9
50.98
ROC (Joel Greenblatt) (%) 132.98
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. LCI: 132.98 )
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.82   Max: 107.31
Current: 132.98

-162.82
107.31
Revenue Growth (3Y)(%) 24.90
LCI's Revenue Growth (3Y)(%) is ranked higher than
92% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. LCI: 24.90 )
LCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.6   Max: 48.4
Current: 24.9

-3.6
48.4
EBITDA Growth (3Y)(%) 152.30
LCI's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. LCI: 152.30 )
LCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 152.3
Current: 152.3

0
152.3
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LCI Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 111,800 sh (-40.66%)
» More
Q2 2014

LCI Guru Trades in Q2 2014

Joel Greenblatt 35,709 sh (New)
Chuck Royce 338,400 sh (New)
Jim Simons Sold Out
» More
Q3 2014

LCI Guru Trades in Q3 2014

Paul Tudor Jones 28,221 sh (New)
Joel Greenblatt 303,345 sh (+749.49%)
Chuck Royce 427,410 sh (+26.30%)
» More
Q4 2014

LCI Guru Trades in Q4 2014

Joel Greenblatt 1,026,029 sh (+238.24%)
Chuck Royce 499,830 sh (+16.94%)
Paul Tudor Jones 31,436 sh (+11.39%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 19.20
LCI's P/E(ttm) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. LCI: 19.20 )
LCI' s 10-Year P/E(ttm) Range
Min: 12.33   Max: 185.79
Current: 19.2

12.33
185.79
Forward P/E 17.95
LCI's Forward P/E is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. LCI: 17.95 )
N/A
PE(NRI) 19.20
LCI's PE(NRI) is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. LCI: 19.20 )
LCI' s 10-Year PE(NRI) Range
Min: 12.32   Max: 222.5
Current: 19.2

12.32
222.5
P/B 6.17
LCI's P/B is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. LCI: 6.17 )
LCI' s 10-Year P/B Range
Min: 0.61   Max: 6.46
Current: 6.17

0.61
6.46
P/S 6.56
LCI's P/S is ranked higher than
55% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. LCI: 6.56 )
LCI' s 10-Year P/S Range
Min: 0.49   Max: 7.09
Current: 6.56

0.49
7.09
PFCF 34.66
LCI's PFCF is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. LCI: 34.66 )
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 34.66

3.21
342.5
POCF 24.91
LCI's POCF is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. LCI: 24.91 )
LCI' s 10-Year POCF Range
Min: 2.86   Max: 577
Current: 24.91

2.86
577
EV-to-EBIT 11.11
LCI's EV-to-EBIT is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. LCI: 11.11 )
LCI' s 10-Year EV-to-EBIT Range
Min: -114.7   Max: 687.5
Current: 11.11

-114.7
687.5
PEG 0.66
LCI's PEG is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 0.66 )
LCI' s 10-Year PEG Range
Min: 0.15   Max: 77.25
Current: 0.66

0.15
77.25
Shiller P/E 79.73
LCI's Shiller P/E is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. LCI: 79.73 )
LCI' s 10-Year Shiller P/E Range
Min: 21.37   Max: 358
Current: 79.73

21.37
358
Current Ratio 7.74
LCI's Current Ratio is ranked higher than
92% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. LCI: 7.74 )
LCI' s 10-Year Current Ratio Range
Min: 0.99   Max: 8.73
Current: 7.74

0.99
8.73
Quick Ratio 6.75
LCI's Quick Ratio is ranked higher than
91% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. LCI: 6.75 )
LCI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 6.75
Current: 6.75

0.26
6.75
Days Inventory 155.45
LCI's Days Inventory is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. LCI: 155.45 )
LCI' s 10-Year Days Inventory Range
Min: 68.82   Max: 174.73
Current: 155.45

68.82
174.73
Days Sales Outstanding 89.70
LCI's Days Sales Outstanding is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. LCI: 89.70 )
LCI' s 10-Year Days Sales Outstanding Range
Min: 34.69   Max: 171.98
Current: 89.7

34.69
171.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.67
LCI's Price/Net Cash is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 16.67 )
LCI' s 10-Year Price/Net Cash Range
Min: 10.91   Max: 42.78
Current: 16.67

10.91
42.78
Price/Net Current Asset Value 8.08
LCI's Price/Net Current Asset Value is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 8.08 )
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 2.02   Max: 91.68
Current: 8.08

2.02
91.68
Price/Tangible Book 6.20
LCI's Price/Tangible Book is ranked higher than
65% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. LCI: 6.20 )
LCI' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 21.7
Current: 6.2

0.9
21.7
Price/DCF (Projected) 5.27
LCI's Price/DCF (Projected) is ranked higher than
77% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. LCI: 5.27 )
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 5.86
Current: 5.27

0.57
5.86
Price/Median PS Value 4.08
LCI's Price/Median PS Value is ranked higher than
52% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. LCI: 4.08 )
LCI' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 6.89
Current: 4.08

0.42
6.89
Price/Peter Lynch Fair Value 0.76
LCI's Price/Peter Lynch Fair Value is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 0.76 )
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 15.96
Current: 0.76

0.5
15.96
Price/Graham Number 2.26
LCI's Price/Graham Number is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. LCI: 2.26 )
LCI' s 10-Year Price/Graham Number Range
Min: 0.93   Max: 6.23
Current: 2.26

0.93
6.23
Earnings Yield (Greenblatt) 9.00
LCI's Earnings Yield (Greenblatt) is ranked higher than
94% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. LCI: 9.00 )
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 9

0.1
14.4
Forward Rate of Return (Yacktman) 55.92
LCI's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. LCI: 55.92 )
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15   Max: 115.5
Current: 55.92

-15
115.5

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 402 455 539 603
EPS($) 3.88 3.65 3.79 3.95
EPS without NRI($) 3.88 3.65 3.79 3.95

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany,
Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma
» More Articles for LCI

Headlines

Articles On GuruFocus.com
Pharmaceutical Stock Picks For March Mar 04 2015 
My Stocks Feb 13 2015 
My Stocks Feb 13 2015 
Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 
comment on LCI Jan 23 2012 

More From Our Partners
Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog Mar 27 2015 - ZACKS

More From Other Websites
Conatus Soars on Positive Phase II Data on Emricasan - Analyst Blog Mar 27 2015
Which 4 Big Drugmakers Have Rising Estimates? Mar 27 2015
Calithera Biosciences (CALA) Crumbles: Stock Falls by 7.3% - Tale of the Tape Mar 27 2015
Agios' PK Deficiency Drug AG-348 Gets Orphan Drug Status - Analyst Blog Mar 26 2015
Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog Mar 26 2015
Oncolytics' Cancer Drug Reolysin Gets Orphan Status in EU - Analyst Blog Mar 26 2015
Indexes Stall Near Flat Line; Lannett Up Some More Mar 26 2015
ZS Pharma (ZSPH) Crumbles: Stock Falls by 9.9% - Tale of the Tape Mar 26 2015
Weakness Seen in Sage Therapeutics (SAGE): Stock Falls 13.2% - Tale of the Tape Mar 26 2015
BioLineRx (BLRX) Looks Good: Stock Moves 9.1% Higher - Tale of the Tape Mar 25 2015
Zafgen (ZFGN) Crumbles: Stock Falls by 7.9% - Tale of the Tape Mar 25 2015
Pfizer & Eli Lilly to Resume Phase III Study of Tanezumab - Analyst Blog Mar 24 2015
Calithera Biosciences (CALA) Jumps: Stock Rises 19% - Tale of the Tape Mar 24 2015
Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog Mar 23 2015
Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog Mar 23 2015
Concert Pharmaceuticals (CNCE) in Focus: Stock Tumbles 10.8% - Tale of the Tape Mar 20 2015
Tetraphase Closes Public Offering, to Raise $173.1M - Analyst Blog Mar 19 2015
Vertex's Kalydeco Gets FDA Nod for Additional Indication - Analyst Blog Mar 19 2015
Retrophin Soars on FDA Approval of Bile Acid Disorder Drug - Analyst Blog Mar 19 2015
Aldeyra Initiates Phase II Sjogren-Larsson Syndrome Study - Analyst Blog Mar 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK